September 5, 2018

Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control

Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity Results support the use of Tumor Treating Fields in first potential indication outside of the… Read More
learn more
September 5, 2018

Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control

Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity Results support the use of Tumor Treating Fields in first potential indication outside of the… Read More
learn more
August 15, 2018

Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer

US Oncology Research will open 10 clinical trial sites, enrolling patients in Novocure’s PANOVA-3 trial to test the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer ST. HELIER, Jersey & THE WOODLANDS, Texas–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) and… Read More
learn more
August 15, 2018

Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer

US Oncology Research will open 10 clinical trial sites, enrolling patients in Novocure’s PANOVA-3 trial to test the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer ST. HELIER, Jersey & THE WOODLANDS, Texas–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) and… Read More
learn more
August 3, 2018

Novocure to Present at Two Upcoming Investor Conferences

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences. Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in the 2018 Wedbush PacGrow Healthcare Conference on Aug. 15, 2018, in New York City. Mr. Groenhuysen’s presentation will begin at 12:45… Read More
learn more
August 3, 2018

Novocure to Present at Two Upcoming Investor Conferences

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences. Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in the 2018 Wedbush PacGrow Healthcare Conference on Aug. 15, 2018, in New York City. Mr. Groenhuysen’s presentation will begin at 12:45… Read More
learn more
August 2, 2018

Novocure Announces Addition to Its Board of Directors

Jeryl Hilleman, Chief Financial Officer of Intersect ENT, elected to board of directors ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure’s board in July 2018. “We are… Read More
learn more
August 2, 2018

Novocure Announces Addition to Its Board of Directors

Jeryl Hilleman, Chief Financial Officer of Intersect ENT, elected to board of directors ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure’s board in July 2018. “We are… Read More
learn more
July 31, 2018

Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer

Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in… Read More
learn more
July 31, 2018

Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer

Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in… Read More
learn more